<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01270321</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00041909</org_study_id>
    <secondary_id>WCI1777-09</secondary_id>
    <nct_id>NCT01270321</nct_id>
  </id_info>
  <brief_title>Pasireotide &amp; Everolimus in Adult Patients With Radioiodine-Refractory Differentiated &amp; Medullary Thyroid Cancer</brief_title>
  <official_title>A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of two anticancer drugs,&#xD;
      everolimus and pasireotide, in patients with thyroid cancer when the cancer is no longer&#xD;
      responding to treatment with radioiodine or where it is deemed unsafe for the patient to&#xD;
      receive additional radioiodine treatment. The investigators also want to establish the best&#xD;
      manner of taking the two medications when used together to treat thyroid cancer. In&#xD;
      particular, the investigators want to know if it is better to give both at the same time or&#xD;
      add a second medication after the first one has stopped working.&#xD;
&#xD;
      This study will also look at specific substances called biomarkers in your blood, and in the&#xD;
      tumor tissue which are involved in the growth of tumor cells, and determine if the levels of&#xD;
      these biomarkers are related to your response to treatment or development of side effects.&#xD;
&#xD;
      Everolimus, also known by the brand name, Afinitor, is a biologic drug approved by the Food&#xD;
      and Drug Administration (FDA) for the treatment of kidney cancer. It works by preventing&#xD;
      cancer cells from multiplying and it also makes them more likely to die from the treatment.&#xD;
&#xD;
      Pasireotide also known by the name, SOM230 is a new medication that is not yet approved by&#xD;
      the FDA for the treatment of cancer. It is a newer form of a drug called octreotide, which is&#xD;
      approved for the treatment of cancer arising from endocrine organs. Pasireotide works by&#xD;
      binding to a protein called somatostatin receptor, which is expressed in many tissues&#xD;
      throughout the body including thyroid cancer cells. Pasireotide prevents the action of&#xD;
      somatostatin by binding to these receptors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Number of participants with response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Progression-free Survival</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Time from starting treatment until disease progression as defined using Response Evaluation CriteriaIn Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&quot;, or death.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (Everolimus alone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Pasireotide alone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Everolimus + Pasireotide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CURRENTLY CLOSED TO ACCRUAL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)</description>
    <arm_group_label>Arm A (Everolimus alone)</arm_group_label>
    <other_name>Afinitor</other_name>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide</intervention_name>
    <description>Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks</description>
    <arm_group_label>Arm B (Pasireotide alone)</arm_group_label>
    <other_name>SOM230</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus and Pasireotide</intervention_name>
    <description>Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks</description>
    <arm_group_label>Arm C (Everolimus + Pasireotide)</arm_group_label>
    <other_name>Afinitor</other_name>
    <other_name>SOM230</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologic or cytologic confirmation of thyroid cancer (papillary, follicular,&#xD;
             medullary); histologic variants such as Hurthle and tall cell variants are allowed.&#xD;
&#xD;
          2. Biochemical or radiologic documentation of disease progression within the last 12&#xD;
             months prior to enrollment.&#xD;
&#xD;
          3. Presence of at least one site of measurable disease according to Response Evaluation&#xD;
             Criteria in Solid Tumors (RECIST) criteria version 1.1.&#xD;
&#xD;
          4. Patient must have radioiodine refractory disease as defined by one or more of the&#xD;
             following conditions:&#xD;
&#xD;
               -  All cases of medullary thyroid carcinoma.&#xD;
&#xD;
               -  No iodine-uptake on a post- radioactive iodine treatment scan (in presence of low&#xD;
                  iodine diet and thyroid stimulating hormone (TSH) suppression) in an anatomically&#xD;
                  defined lesion that qualifies as target lesion by RECIST criteria.&#xD;
&#xD;
             OR&#xD;
&#xD;
             • If there is demonstrable iodine-uptake: the last radioiodine therapy of (≥ 100 mCi)&#xD;
             was given within the last 16 months OR if given more than 16 months before enrollment,&#xD;
             there is evidence of disease progression after each of the last two radioiodine&#xD;
             treatment performed within 16 months of each other (each dose should be ≥ 100mCi).&#xD;
&#xD;
             OR&#xD;
&#xD;
               -  If the patient has received the maximum cumulative life time dose of radioactive&#xD;
                  iodine treatments of at least 600 mCi.&#xD;
&#xD;
               -  If the patient declines or is intolerant of radioiodine therapy or if with&#xD;
                  progressive disease that is, in the opinion of the treating physician, likely to&#xD;
                  benefit from biologic therapy rather than further iodine therapy e.g. patient&#xD;
                  with heavy burden of disease&#xD;
&#xD;
          5. Age ≥ 18 years.&#xD;
&#xD;
          6. Minimum of four weeks since any major surgery or since completion of radiation&#xD;
             (patients should have adequately recovered from the acute toxicities of any prior&#xD;
             therapy).&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.&#xD;
&#xD;
          8. Life expectancy of at least 6 months.&#xD;
&#xD;
          9. Adequate bone marrow function as shown by: absolute neutrophil count (ANC) ≥ 1.5 x&#xD;
             10⁹/L, platelets ≥ 100 x 10⁹/L, Hgb &gt; 9 g/dL.&#xD;
&#xD;
         10. Adequate liver function as shown by: serum bilirubin ≤ 1.5 x upper limit of normal&#xD;
             (ULN), and serum transaminases activity ≤ 3 x ULN, with the exception of serum&#xD;
             transaminases (&lt; 5 x ULN) if the patient has liver metastases.&#xD;
&#xD;
         11. Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN or glomerular&#xD;
             filtration rate (GFR) of 60cc/ml using the formula of Cockroft and Gault.&#xD;
&#xD;
         12. Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5&#xD;
             x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can&#xD;
             only be included after initiation of appropriate lipid lowering medication.&#xD;
&#xD;
         13. Women of childbearing potential must have a negative serum pregnancy test within 14&#xD;
             days of the administration of the first study treatment. Women must not be lactating.&#xD;
             Both men and women of childbearing potential must be advised of the importance of&#xD;
             using effective birth control measures during the course of the study.&#xD;
&#xD;
         14. Signed informed consent to participate in the study must be obtained from patients&#xD;
             after they have been fully informed of the nature and potential risks by the&#xD;
             investigator (or his/her designee) with the aid of written information.&#xD;
&#xD;
         15. International normalized ratio (INR) and prothrombin time (PTT) ≤ 1.5 x ULN.&#xD;
             (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a&#xD;
             stable dose of low molecular weight [LMW] heparin for &gt; 2 weeks at time of&#xD;
             randomization.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with not more than 1 systemic agent.&#xD;
&#xD;
          2. Patients who have undergone major surgery within 4 weeks prior to study enrollment&#xD;
             (tracheotomy, feeding tube or vascular access catheter placement and interventional&#xD;
             procedures such as bronchoscopy, upper GI endoscopy or colonoscopy are not considered&#xD;
             major surgery).&#xD;
&#xD;
          3. Chronic treatment with systemic steroids or another immunosuppressive agent.&#xD;
&#xD;
          4. Patients should not receive immunization with attenuated live vaccines during study&#xD;
             period or within 1 week of study entry.&#xD;
&#xD;
          5. Uncontrolled brain or leptomeningeal metastases, including patients who continue to&#xD;
             require glucocorticoids for brain or leptomeningeal metastases.&#xD;
&#xD;
          6. Patients with prior or concurrent malignancy except for the following: adequately&#xD;
             treated basal cell or squamous cell skin cancer, or other adequately treated in situ&#xD;
             cancer, or any other cancer from which the patient has been disease free for five&#xD;
             years.&#xD;
&#xD;
          7. Patients with uncontrolled diabetes mellitus or a fasting plasma glucose &gt; 1.5 ULN.&#xD;
             Note: At the principal investigator's discretion, non-eligible patients can be&#xD;
             re-screened after adequate medical therapy has been instituted.&#xD;
&#xD;
          8. Patients with symptomatic cholelithiasis (asymptomatic gall stone discovered on&#xD;
             screening US should be reviewed by the PI but will not lead to automatic exclusion).&#xD;
&#xD;
          9. Liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C):&#xD;
&#xD;
               -  History of liver disease, such as cirrhosis or chronic active hepatitis B and C.&#xD;
&#xD;
               -  Presence of Hepatitis B surface antigen (HbsAg).&#xD;
&#xD;
               -  Presence of Hepatitis C antibody test (anti-HCV).&#xD;
&#xD;
         10. Patients who have congestive heart failure (NYHA Class III or IV), unstable angina,&#xD;
             sustained ventricular tachycardia, ventricular fibrillation, clinically significant&#xD;
             bradycardia, advanced heart block or a history of acute myocardial infarction within&#xD;
             the six months preceding enrollment.&#xD;
&#xD;
         11. QT related exclusion criteria:&#xD;
&#xD;
               -  QT corrected Fridericia's method (QTcF) at screening &gt; 470 msec.&#xD;
&#xD;
               -  History of syncope or family history of idiopathic sudden death.&#xD;
&#xD;
               -  Sustained or clinically significant cardiac arrhythmias.&#xD;
&#xD;
               -  Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac&#xD;
                  failure, clinically significant/symptomatic bradycardia, or high-grade&#xD;
                  atrioventricular (AV) block.&#xD;
&#xD;
               -  Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused&#xD;
                  by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism&#xD;
                  or cardiac failure.&#xD;
&#xD;
               -  Concomitant medication(s) known to increase the QT interval.&#xD;
&#xD;
         12. Patients with the presence of active or suspected acute or chronic uncontrolled&#xD;
             infection or with a history of immunocompromise, including a positive HIV test result&#xD;
             (ELISA and Western blot).&#xD;
&#xD;
         13. Patients who have any severe and/or uncontrolled medical conditions or other&#xD;
             conditions that could affect their participation in the study such as:&#xD;
&#xD;
               -  Severely impaired lung function (as defined as spirometry and diffusing capacity&#xD;
                  of lung for carbon monoxide [DLCO] that is 50% of the normal predicted value&#xD;
                  and/or 02 saturation that is 88% or less at rest on room air).&#xD;
&#xD;
               -  Any active (acute or chronic) or uncontrolled infection/disorders.&#xD;
&#xD;
               -  Nonmalignant medical illnesses that are uncontrolled or whose control may be&#xD;
                  jeopardized by the treatment with the study therapy.&#xD;
&#xD;
               -  Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
                  significantly alter the absorption of RAD001 (everolimus).&#xD;
&#xD;
               -  Patients who have a history of alcohol or drug abuse in the 6 month period prior&#xD;
                  to receiving treatment with pasireotide or RAD001.&#xD;
&#xD;
               -  History of, or current alcohol misuse/abuse within the past 12 months.&#xD;
&#xD;
               -  Acute or chronic pancreatitis.&#xD;
&#xD;
         14. Women who are pregnant or breast feeding, or women/men of reproductive potential who&#xD;
             are not using and unwilling to practice an effective method of birth control. (Women&#xD;
             of childbearing potential [WOCBP] must have a negative serum pregnancy test within 7&#xD;
             days prior to administration of pasireotide and RAD001.)&#xD;
&#xD;
         15. Male patient whose sexual partner(s) are WOCBP who are not willing to use adequate&#xD;
             contraception, during the study and for 8 weeks after the end of treatment.&#xD;
&#xD;
         16. Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins&#xD;
             (sirolimus, temsirolimus) or to its excipients.&#xD;
&#xD;
         17. Known hypersensitivity to somatostatin analogues or any component of the pasireotide&#xD;
             or octreotide LAR formulations.&#xD;
&#xD;
         18. History of noncompliance to medical regimens.&#xD;
&#xD;
         19. Patients unwilling to or unable to comply with the protocol.&#xD;
&#xD;
         20. Patients taking medications known to be strong cytochrome P450, family 3, subfamily A&#xD;
             (CYP3A) inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taofeek Owonikoko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Winship Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2011</study_first_posted>
  <results_first_submitted>May 14, 2020</results_first_submitted>
  <results_first_submitted_qc>August 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2020</results_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Taofeek K. Owonikoko</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Thyroid Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Pasireotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 8, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT01270321/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled between 11/17/2010 and 1/2/2019 at Winship Cancer Institute of Emory University</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Everolimus Alone)</title>
          <description>CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression&#xD;
Everolimus: Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Pasireotide Alone)</title>
          <description>CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression&#xD;
Pasireotide: Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Arm C (Everolimus + Pasireotide)</title>
          <description>CURRENTLY CLOSED TO ACCRUAL&#xD;
Everolimus and Pasireotide: Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A (Everolimus Alone)</title>
          <description>CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression&#xD;
Everolimus: Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)</description>
        </group>
        <group group_id="B2">
          <title>Arm B (Pasireotide Alone)</title>
          <description>CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression&#xD;
Pasireotide: Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Arm C (Everolimus + Pasireotide)</title>
          <description>CURRENTLY CLOSED TO ACCRUAL&#xD;
Everolimus and Pasireotide: Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>The measure of dispersion data are not available. All efforts were made to obtain these data from the PI and the study documentation.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.95" spread="NA">There is no standard deviation for this trial</measurement>
                    <measurement group_id="B2" value="64.73" spread="NA">There is no standard deviation for this trial</measurement>
                    <measurement group_id="B3" value="58.83" spread="NA">There is no standard deviation for this trial</measurement>
                    <measurement group_id="B4" value="60.75" spread="NA">There is no standard deviation for this trial</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0)</title>
        <description>Number of participants with response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Everolimus Alone)</title>
            <description>CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression&#xD;
Everolimus: Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)&#xD;
Most frequent adverse events in &gt;20% of patients:&#xD;
Dry skin&#xD;
Dysgeusia&#xD;
Hypoalbuminemia&#xD;
Joint Pain&#xD;
Cough&#xD;
Diarrhea&#xD;
Hypercholesterolemia&#xD;
Hypertriglceridemia&#xD;
Hypokalemia&#xD;
Hyponatremiapnia&#xD;
Mucositis&#xD;
Rash&#xD;
Thrombocyto</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Pasireotide Alone)</title>
            <description>CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression&#xD;
Pasireotide: Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks.&#xD;
Most frequent adverse events in &gt;20% of patients:&#xD;
Hyperbilirubinemia&#xD;
Hypertriglyceridemia&#xD;
Hypercholesterolemia</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Everolimus + Pasireotide)</title>
            <description>CURRENTLY CLOSED TO ACCRUAL&#xD;
Everolimus and Pasireotide: Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks.&#xD;
Most frequent adverse events in &gt;20% of patients:&#xD;
Hypercholesterolemia&#xD;
Anemia&#xD;
Headache&#xD;
Decreased Appetite&#xD;
Cough&#xD;
Mucositis&#xD;
Hyponatremia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0)</title>
          <description>Number of participants with response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Progression-free Survival</title>
        <description>Time from starting treatment until disease progression as defined using Response Evaluation CriteriaIn Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&quot;, or death.</description>
        <time_frame>Through study completion, an average of 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Everolimus Alone)</title>
            <description>CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression&#xD;
Everolimus: Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)&#xD;
Most frequent adverse events in &gt;20% of patients:&#xD;
Dry skin&#xD;
Dysgeusia&#xD;
Hypoalbuminemia&#xD;
Joint Pain&#xD;
Cough&#xD;
Diarrhea&#xD;
Hypercholesterolemia&#xD;
Hypertriglceridemia&#xD;
Hypokalemia&#xD;
Hyponatremiapnia&#xD;
Mucositis&#xD;
Rash&#xD;
Thrombocyto</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Pasireotide Alone)</title>
            <description>CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression&#xD;
Pasireotide: Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks.&#xD;
Most frequent adverse events in &gt;20% of patients:&#xD;
Hyperbilirubinemia&#xD;
Hypertriglyceridemia&#xD;
Hypercholesterolemia</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Everolimus + Pasireotide)</title>
            <description>CURRENTLY CLOSED TO ACCRUAL&#xD;
Everolimus and Pasireotide: Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks.&#xD;
Most frequent adverse events in &gt;20% of patients:&#xD;
Hypercholesterolemia&#xD;
Anemia&#xD;
Headache&#xD;
Decreased Appetite&#xD;
Cough&#xD;
Mucositis&#xD;
Hyponatremia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression-free Survival</title>
          <description>Time from starting treatment until disease progression as defined using Response Evaluation CriteriaIn Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&quot;, or death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected through study completion, an average of 1 year.</time_frame>
      <desc>Any undesirable any unfavorable signs or symptom reported by the patient while on study drug .</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A (Everolimus Alone)</title>
          <description>CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression&#xD;
Everolimus: Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)</description>
        </group>
        <group group_id="E2">
          <title>Arm B (Pasireotide Alone)</title>
          <description>CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression&#xD;
Pasireotide: Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Arm C (Everolimus + Pasireotide)</title>
          <description>CURRENTLY CLOSED TO ACCRUAL&#xD;
Everolimus and Pasireotide: Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Taofeek Owonikoko</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-5575</phone>
      <email>TOWONIK@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

